Meghan Jude Mooradian, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 15 | 2024 | 5706 | 1.580 |
Why?
|
Proto-Oncogene Proteins B-raf | 6 | 2024 | 2059 | 1.220 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 16 | 2024 | 5432 | 1.140 |
Why?
|
Lung Neoplasms | 22 | 2024 | 13586 | 1.080 |
Why?
|
Colitis | 4 | 2021 | 1242 | 0.660 |
Why?
|
Cryosurgery | 1 | 2024 | 479 | 0.650 |
Why?
|
Mucositis | 1 | 2020 | 108 | 0.640 |
Why?
|
Polymyalgia Rheumatica | 1 | 2018 | 52 | 0.610 |
Why?
|
Protein Kinase Inhibitors | 6 | 2024 | 5703 | 0.590 |
Why?
|
Celiac Disease | 2 | 2022 | 820 | 0.550 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 219 | 0.500 |
Why?
|
Combined Modality Therapy | 9 | 2024 | 8542 | 0.450 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.430 |
Why?
|
Molecular Targeted Therapy | 4 | 2024 | 2830 | 0.430 |
Why?
|
Antibodies, Monoclonal | 5 | 2024 | 9263 | 0.380 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2024 | 637 | 0.360 |
Why?
|
Glucocorticoids | 1 | 2020 | 2167 | 0.350 |
Why?
|
Tumor Microenvironment | 8 | 2024 | 3948 | 0.340 |
Why?
|
Neoplasms | 10 | 2024 | 22371 | 0.340 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1627 | 0.330 |
Why?
|
Skin Neoplasms | 8 | 2024 | 5863 | 0.330 |
Why?
|
Oximes | 2 | 2023 | 303 | 0.330 |
Why?
|
Immunotherapy | 8 | 2023 | 4755 | 0.320 |
Why?
|
Adenocarcinoma | 4 | 2021 | 6395 | 0.310 |
Why?
|
Pyrimidinones | 2 | 2023 | 386 | 0.310 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4206 | 0.300 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2015 | 271 | 0.290 |
Why?
|
Hospitalization | 3 | 2024 | 10840 | 0.260 |
Why?
|
Pyridones | 2 | 2023 | 819 | 0.250 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 1105 | 0.240 |
Why?
|
Neoplasm Metastasis | 4 | 2024 | 4912 | 0.240 |
Why?
|
Aged | 26 | 2024 | 171504 | 0.220 |
Why?
|
Humans | 62 | 2024 | 768166 | 0.220 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6974 | 0.210 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3781 | 0.210 |
Why?
|
Oncolytic Virotherapy | 2 | 2019 | 520 | 0.200 |
Why?
|
Retrospective Studies | 22 | 2024 | 81762 | 0.200 |
Why?
|
Aged, 80 and over | 12 | 2024 | 59629 | 0.190 |
Why?
|
Thyroiditis | 1 | 2021 | 86 | 0.180 |
Why?
|
Duodenitis | 1 | 2020 | 20 | 0.180 |
Why?
|
Biopsy | 4 | 2020 | 6793 | 0.170 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.170 |
Why?
|
Middle Aged | 24 | 2024 | 223492 | 0.170 |
Why?
|
Phospholipase D | 1 | 2019 | 70 | 0.170 |
Why?
|
Enterocolitis | 1 | 2020 | 106 | 0.160 |
Why?
|
Male | 29 | 2024 | 364719 | 0.160 |
Why?
|
Exanthema | 1 | 2024 | 503 | 0.160 |
Why?
|
Genes, cdc | 1 | 2019 | 113 | 0.160 |
Why?
|
OX40 Ligand | 1 | 2019 | 57 | 0.160 |
Why?
|
Hepatitis | 1 | 2021 | 227 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11878 | 0.160 |
Why?
|
Acute Kidney Injury | 2 | 2022 | 1942 | 0.150 |
Why?
|
Disease Progression | 5 | 2024 | 13671 | 0.150 |
Why?
|
International Classification of Diseases | 1 | 2024 | 937 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2021 | 255 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 117 | 0.150 |
Why?
|
Adjuvants, Immunologic | 1 | 2023 | 998 | 0.150 |
Why?
|
Neoplasm Staging | 5 | 2024 | 11244 | 0.150 |
Why?
|
Clinical Trials as Topic | 4 | 2019 | 8054 | 0.140 |
Why?
|
Budgets | 1 | 2019 | 232 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5341 | 0.140 |
Why?
|
Female | 28 | 2024 | 397192 | 0.140 |
Why?
|
Patient Simulation | 1 | 2019 | 297 | 0.140 |
Why?
|
Radiosurgery | 1 | 2016 | 1330 | 0.140 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2022 | 521 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
Neurotoxicity Syndromes | 1 | 2020 | 302 | 0.130 |
Why?
|
Toll-Like Receptors | 1 | 2019 | 582 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 4058 | 0.120 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 551 | 0.120 |
Why?
|
Treatment Outcome | 11 | 2024 | 65371 | 0.120 |
Why?
|
Adult | 16 | 2024 | 223646 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 348 | 0.120 |
Why?
|
Tumor Escape | 1 | 2017 | 372 | 0.120 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2019 | 1245 | 0.110 |
Why?
|
Drug Resistance | 1 | 2020 | 1599 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2019 | 1791 | 0.110 |
Why?
|
Abdominal Pain | 1 | 2020 | 1070 | 0.110 |
Why?
|
Lung Diseases, Interstitial | 1 | 2022 | 940 | 0.110 |
Why?
|
Psoriasis | 1 | 2021 | 926 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 716 | 0.110 |
Why?
|
Diarrhea | 1 | 2020 | 1320 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7454 | 0.110 |
Why?
|
Brachytherapy | 1 | 2021 | 1220 | 0.110 |
Why?
|
Prognosis | 7 | 2022 | 30010 | 0.110 |
Why?
|
Mutation | 5 | 2024 | 30238 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1169 | 0.100 |
Why?
|
Skin Diseases | 1 | 2021 | 1085 | 0.100 |
Why?
|
Intestinal Mucosa | 2 | 2020 | 3044 | 0.100 |
Why?
|
Colon | 1 | 2020 | 1801 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1426 | 0.100 |
Why?
|
Immune System | 1 | 2017 | 799 | 0.100 |
Why?
|
Colonoscopy | 1 | 2020 | 1409 | 0.100 |
Why?
|
Myocarditis | 1 | 2019 | 802 | 0.100 |
Why?
|
Ultrasonography | 1 | 2024 | 6004 | 0.090 |
Why?
|
Antigens, CD | 1 | 2021 | 4035 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2021 | 1402 | 0.090 |
Why?
|
Drug Costs | 1 | 2019 | 1195 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1662 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2163 | 0.090 |
Why?
|
Cell Communication | 1 | 2017 | 1660 | 0.090 |
Why?
|
Quinazolines | 1 | 2016 | 1373 | 0.080 |
Why?
|
Cohort Studies | 5 | 2024 | 41754 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20760 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2017 | 1041 | 0.080 |
Why?
|
Proteomics | 1 | 2023 | 3912 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1613 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 1 | 2019 | 2056 | 0.080 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1512 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2536 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2346 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13676 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9419 | 0.070 |
Why?
|
Skin | 1 | 2021 | 4503 | 0.070 |
Why?
|
Myocardium | 1 | 2019 | 4788 | 0.070 |
Why?
|
Models, Economic | 2 | 2019 | 719 | 0.060 |
Why?
|
Australia | 2 | 2018 | 1265 | 0.060 |
Why?
|
Pain | 1 | 2019 | 5100 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 93 | 0.060 |
Why?
|
Cytokines | 1 | 2019 | 7453 | 0.060 |
Why?
|
DNA | 1 | 2017 | 7214 | 0.050 |
Why?
|
Synovitis | 1 | 2024 | 217 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2018 | 6847 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 514 | 0.050 |
Why?
|
Taxoids | 1 | 2016 | 667 | 0.050 |
Why?
|
Consensus | 2 | 2024 | 3212 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11095 | 0.050 |
Why?
|
Musculoskeletal System | 1 | 2024 | 188 | 0.050 |
Why?
|
Prospective Studies | 4 | 2022 | 54926 | 0.050 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 5536 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16726 | 0.050 |
Why?
|
Time Factors | 5 | 2021 | 40218 | 0.040 |
Why?
|
Survival Analysis | 3 | 2018 | 10101 | 0.040 |
Why?
|
Oncogenes | 1 | 2016 | 1234 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 49 | 0.040 |
Why?
|
Young Adult | 4 | 2020 | 60066 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4860 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 879 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2024 | 1062 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Microvilli | 1 | 2020 | 235 | 0.040 |
Why?
|
Patient Care Team | 2 | 2021 | 2523 | 0.040 |
Why?
|
Inpatients | 2 | 2021 | 2566 | 0.040 |
Why?
|
Arthritis | 1 | 2024 | 684 | 0.040 |
Why?
|
Tomography | 1 | 2021 | 442 | 0.040 |
Why?
|
Incidence | 3 | 2022 | 21538 | 0.040 |
Why?
|
Polyneuropathies | 1 | 2019 | 139 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10399 | 0.040 |
Why?
|
Quality of Life | 3 | 2023 | 13490 | 0.040 |
Why?
|
United States | 6 | 2020 | 73039 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2018 | 252 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 797 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2024 | 1238 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2024 | 1203 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 979 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2080 | 0.030 |
Why?
|
SEER Program | 1 | 2020 | 1444 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2019 | 1836 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 13014 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12840 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2810 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 552 | 0.030 |
Why?
|
Intestine, Small | 1 | 2020 | 1217 | 0.030 |
Why?
|
Creatinine | 1 | 2019 | 1918 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 925 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1321 | 0.030 |
Why?
|
Recurrence | 1 | 2015 | 8509 | 0.030 |
Why?
|
Risk Factors | 4 | 2021 | 74944 | 0.030 |
Why?
|
Chest Pain | 1 | 2019 | 1101 | 0.030 |
Why?
|
Lung | 2 | 2022 | 10099 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1741 | 0.020 |
Why?
|
Paclitaxel | 1 | 2019 | 1733 | 0.020 |
Why?
|
Dyspnea | 1 | 2019 | 1352 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2020 | 2323 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3436 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2227 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 1886 | 0.020 |
Why?
|
Animals | 2 | 2024 | 169246 | 0.020 |
Why?
|
Signal Transduction | 2 | 2018 | 23645 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 24315 | 0.020 |
Why?
|
Mortality | 1 | 2020 | 2911 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2008 | 0.020 |
Why?
|
Age Factors | 1 | 2015 | 18412 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8890 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4648 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6526 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2024 | 10266 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2024 | 4887 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10632 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6412 | 0.020 |
Why?
|
Apoptosis | 1 | 2019 | 9523 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2257 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12543 | 0.010 |
Why?
|
Registries | 1 | 2019 | 8375 | 0.010 |
Why?
|
Pilot Projects | 1 | 2016 | 8741 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15454 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15948 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8748 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2021 | 26422 | 0.010 |
Why?
|
Adolescent | 2 | 2019 | 89169 | 0.010 |
Why?
|
Mice | 1 | 2024 | 82029 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39348 | 0.010 |
Why?
|